The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Drug UPDATES

Drug UPDATES

March 18, 2011 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

New Drug Approvals

New drug approvals were down in 2010, according to the U.S. Food and Drug Administration (FDA).1 Those in the agency and its drug reviewers continued to provide rigorous analyses of drug safety in 2010. Accordingly, it appears that only 21 drugs were approved in 2010, which is down from 2009 and 2008, when 25 and 24 drugs were FDA approved, respectively. Looking back over the past year, new approvals were dominated by new generic approvals, new dosage forms, and new indications. The new indications category included agents that were new molecular entities such as denosumab and new indications for those entities.2 You will see from this month’s limited list of new approvals and agents in the pipeline a pattern similar to that of 2010, with more focus on safety. In the next few years, the focus of new approvals will likely trend towards more biologics and/or specialty agents, with safety and manufacturer risk evaluation and mitigation strategies (REMS) in place to ensure that a product’s risks do not outweigh its benefits.3,4

You Might Also Like
  • Drug Updates
  • Drug Updates
  • Rheumatology Drug Updates
Explore This Issue
March 2011
Also By This Author
  • Ustekinumab Has Longer Efficacy Duration than TNFIs for Plaque Psoriasis

Fentanyl transmucosal tablet (Abstral) has been FDA approved to treat breakthrough pain in cancer patients who already use and can tolerate around-the-clock opioids.5 The FDA is requiring that all patients using this agent enroll in a REMS program to prevent misuse of the agent. The REMS program consists of a Patient–Prescriber Agreement and an enrollment form. The FDA is asking that all manufacturers of opioids develop and utilize a single shared REMS implementation system. Fentanyl is already FDA approved as a buccal tablet and as a patch, but there have been a number of recalls on the patch due to drug leakage. There also have been issues related to misuse of fentanyl products. Patients who are not opioid tolerant should not use this product due to the potential for respiratory depression and/or death. In 2005, fentanyl patches had been linked to 120 deaths. Although approved in cancer patients, there is always the potential that other opioid-tolerant chronic-pain patients may receive this agent.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Pantoprazole delayed-release tablets (generic Protonix) have been FDA approved.6

Tocilizumab (Actemra) has received a supplemental approval from the FDA for inhibition and slowing of structural joint damage, improvement of physical functioning, and achieving major clinical response in adults with moderately to severely active rheumatoid arthritis (RA), when combined with methotrexate treatment.7

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pipeline

The FDA has extended the date of its priority review of belimumab injection (Benlysta) for treating systemic lupus erythematosus to March 10, 2011. The FDA had requested additional information on the drug, which its manufacturer, GlaxoSmithKline and Human Genome Sciences, has since provided.8 Final word on its approval should come soon.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Drug Updates, Safety Tagged With: Approvals, Drugs, FDA, SafetyIssue: March 2011

You Might Also Like:
  • Drug Updates
  • Drug Updates
  • Rheumatology Drug Updates
  • Rheumatology Drug Updates, Trials, Safety Data

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.